Bionano Genomics is on a strong upward trajectory, with optical genome mapping technology gaining serious clinical traction. Q2 results show 30% year-over-year growth in consumable sales—now $4.3 million—and a 27% jump in flow cell sales, outpacing supply. The company’s strategy of deepening platform adoption is paying off, fueled by mounting evidence of OGM’s accuracy in cancer and genetic disorders, plus new reimbursement codes accelerating real-world use. Financially, gross margins hit a record 53%, expenses are under control, and they’ve retired key debt—moving closer to profitability. With Dr. Alex Hastie returning as CSO to bolster scientific leadership and an interim CEO guiding the search for a permanent CEO, Bionano is focused on scaling existing systems while ramping up production to meet demand.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
